| Literature DB >> 32621089 |
Anna Szurpnicka1, Anna Kowalczuk2, Arkadiusz Szterk3.
Abstract
Mistletoe has been used as treatment of many diseases in traditional and folk medicine. To date, anticancer, immunomodulatory, cardiac, antidiabetic, hepatoprotective, neuropharmacological, antibacterial and antifungal properties of mistletoe extracts have been studied the most. In this review, we summarized in vitro and in vivo studies on the pharmacological activity of Viscum species. Furthermore, we proposed the possible mechanisms of action of this herb, which might include many signalling pathways. Mistletoe could regulate either similar or different targets in various pathways that act on membrane receptors, enzymes, ion channels, transporter proteins and transcriptional targets. Still, pharmacological activities of mistletoe have been investigated mainly for crude extracts. It is a new field for scientists to determined which chemical compounds are responsible for the individual biological activities of mistletoe and how these activities are achieved. As a result, mistletoe might become a source of new complementary therapies supporting the treatment of many diseases.Entities:
Keywords: Bioactivities; Extracts; Mechanisms; Mistletoe; Pharmacognosy; Viscum
Mesh:
Year: 2020 PMID: 32621089 PMCID: PMC7340679 DOI: 10.1007/s12272-020-01247-w
Source DB: PubMed Journal: Arch Pharm Res ISSN: 0253-6269 Impact factor: 4.946
Fig. 1Mechanism of anticancer activity of mistletoe. Mistletoe targets two important signalling pathways, PI3K/AKT and MAPK. PI3K/AKT pathway is responsible for growth and survival of cancer cells. Mistletoe induces apoptosis by inhibition of AKT phosphorylation. MAPK pathway is mediated by ERK, p38 and JNK. Mistletoe enhances p38 and JNK1 activation and reduces ERK leading to apoptosis and cell cycle arrest of cancer cells. a Mistletoe downregulates cyclins (CCND1, CCNE, CCNA) and cyclin-dependent protein kinases (CDK4, CDK2) inhibiting cell cycle. b Mistletoe upregulates proapoptotic proteins (Bax) and downregulates inhibitors of apoptosis (IAPs) such as BCL2, BCL2L1, MCL1, XIAP. Furthermore, mistletoe leads to release of cytochrome c and activation of caspases resulting in apoptosis
Antitumor activity of Viscum species—in vitro studies
| Mechanism of action | Preparation/compound (host tree) | Concentration of the extract/compound | Cell line | Observations | References |
|---|---|---|---|---|---|
| Cell cycle | Extract containing 10 ng/mL lectin MLI Extract containing 60 µg/mL oleanolic acid Extract containing 5 ng/mL lectin MLI and 50 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B, Saos-2 and U2OS | G1 arrest in TP53 wild-type (U2OS) and null-mutant (Saos-2) cells, S arrest in TP53 mutant cells (143B), blockage of G1/S transition accompanied by downregulation of CDK4, CCND1, CDK2, CCNE, CCNA, investigations on the transcriptional level revealed secondary TP53 participation, cell cycle arrest was mediated by transcriptionally increased expression of GADD45A and CDKN1A and decreased SKP2 levels | Kleinsimon et al. ( | |
| 3% and 5% v/v | Murine melanoma cell line B16F10 | Increased Sub G0 population, probably associated with a consistent decrease in G1, and an increase in S or G2/M populations | Melo et al. ( | ||
| 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | G2/M cell cycle arrest with a concomitant decrease in some cells at G0/G1 phase | Mishra et al. ( | ||
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Cell cycle arrest in A549 and NCI- H292 cells at the S and G0/G1 phases, respectively | Fan et al. ( | |
Lectin 10–1000 ng/mL Extract 10–1000 µg/mL | Mouse melanoma cell lines B16BL6 and B16F10 | G0/G1 cell cycle arrest | Han et al. ( | ||
| MMP | 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | Loss of MMP, which is required for cytochrome c release | Mishra et al. ( | |
(apple tree) | Extract containing 1.25–7.5 ng/mL lectin MLI Extract containing 30–45 µg/mL oleanolic acid Extract containing 1.25–7.5 ng/mL lectin MLI and 30–45 µg/mL oleanolic acid | Human alveolar Rhabdomyosarcoma cell line RMS-13 | Stammer et al. ( | ||
(apple tree) | Extract containing 1–40 ng/mL lectin MLI Extract containing 10–60 µg/mL oleanolic acid Extract containing 1–40 ng/mL lectin MLI and 10–60 µg/mL oleanolic acid | Human Ewing sarcoma cell lines TC-71 and MHH-ES-1 | Twardziok et al. ( | ||
Extract containing 2–16 ng/mL lectin MLI Extract containing 20–40 µg/mL oleanolic acid Extract containing 2–16 ng/mL lectin MLI and 20–40 µg/mL oleanolic acid | Human acute myeloid leukemia cell lines U937 and HL-60 | Delebinski et al. ( | |||
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Fan et al. ( | ||
Extract containing 2.5–10 ng/mL lectin MLI Extract containing 40–60 µg/mL oleanolic acid Extract containing 2.5–10 ng/mL lectin MLI and 40–60 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B and Saos-2 | Kleinsimon et al. ( | |||
| Cytochrome | Extract containing 4–8 ng/mL lectin MLI Extract containing 25–35 µg/mL oleanolic acid Extract containing 4–8 ng/mL lectin MLI and 25–35 µg/mL oleanolic acid | Human acute myeloid leukemia cell lines U937 and HL-60 | Release of cytochrome c | Delebinski et al. ( | |
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Release of cytochrome c and AIF | Fan et al. ( | |
| MAPK/JNK, ERK and p38 | Lectin II isolated from | 100 ng/mL | Human myeloid leukemia cell line U937 | Increased phosphorylation of the JNK1 substrate, GST-c-Jun N-terminal protein | Park et al. ( |
| Abnoba | 20 µg/mL | Human myeloid leukemia cell line K562 | Increased phosphorylation of JNK1 and p38, reduced levels of phosphorylated ERK-1/2 | Park et al. ( | |
Extract containing 1–40 ng/mL lectin MLI Extract containing 10–60 µg/mL oleanolic acid Extract containing 1–40 ng/mL lectin MLI and 10–60 µg/mL oleanolic acid | Human Ewing sarcoma cell lines TC-71 and MHH-ES-1 | Increased phosphorylation of JNK1 and p38 | Twardziok et al. ( | ||
Extract containing 10 ng/mL lectin MLI Extract containing 60 µg/mL oleanolic acid Extract containing 5 ng/mL lectin MLI and 50 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B, Saos-2 and U2OS | Activation of JNK1 with simultaneous inactivation of ERK-1/2 | Kleinsimon et al. ( | ||
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Upregulation of the expression levels of p-ERK1/2 and p-P90RSK | Fan et al. ( | |
| PI3K/AKT | 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Downregulation of the phosphorylation of AKT and P70RSK | Fan et al. ( |
| Lectin isolated from | 10 ng/mL | Human cancer cell line A253 | Dephosphorylation of AKT | Choi et al. ( | |
Iscador Qu Spezial (oak) Iscador M (apple tree) | 0.3 mg/mL | Human tongue cancer cell lines SCC9 and SCC25 | Reduced pAKT | Klingbeil et al. ( | |
| Abnoba | 20 µg/mL | Human myeloid leukemia cell line K562 | Reduced levels of phosphorylated AKT | Park et al. ( | |
| COX-2 | VA Qu Spez (oak) | 10–100 µg/mL | Human lung adenocarcinoma cell line A549 | Inhibition of the secretion of IL-1β-induced PGE2 associated with a reduced expression of COX-2 | Hegde et al. ( |
| Caspases | Extract containing 2–16 ng/mL lectin MLI Extract containing 20–40 µg/mL oleanolic acid Extract containing 2–16 ng/mL lectin MLI and 20–40 µg/mL oleanolic acid | Human acute myeloid leukemia cell line HL-60 | Activation of caspase-8 and caspase -9 | Delebinski et al. ( | |
| 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | Activation of caspase-8 and caspase-3 | Mishra et al. ( | ||
Extract containing 1.25–7.5 ng/mL lectin MLI Extract containing 30–45 µg/mL oleanolic acid Extract containing 1.25–7.5 ng/mL lectin MLI and 30–45 µg/mL oleanolic acid | Human alveolar Rhabdomyosarcoma cell line RMS-13 | Activation of caspase-9, caspase-8 and caspase-3 | Stammer et al. ( | ||
Extract containing 1–40 ng/mL lectin MLI Extract containing 10–60 µg/mL oleanolic acid Extract containing 1–40 ng/mL lectin MLI and 10–60 µg/mL oleanolic acid | Human Ewing sarcoma cell lines TC-71 and MHH-ES-1 | Activation of caspase-9, caspase-8 | Twardziok et al. ( | ||
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Activation of caspase-9 and caspase-3 | Fan et al. ( | |
| Abnoba | 20 µg/mL | Human myeloid leukemia cell line K562 | Decreased expression of procaspase-9 but increased that of cleaved (active) caspase-9 | Park et al. ( | |
| Lectin isolated from | 10 ng/mL | Human cancer cell line A253 | Activation of caspase-3 | Choi et al. ( | |
Extract containing 2.5–10 ng/mL lectin MLI Extract containing 40–60 µg/mL oleanolic acid Extract containing 2.5–10 ng/mL lectin MLI and 40–60 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B and Saos-2 | Activation of caspase-8 and caspase-9 | Kleinsimon et al. ( | ||
Lectin 10–1000 ng/mL Extract 10–1000 µg/mL | Mouse melanoma cell lines B16BL6 and B16F10 | Activation of caspase-1, 3, 4, 5, 6, 7, 8, and 9 | Han et al. ( | ||
| Antiapoptotic proteins | Extract containing 40 ng/mL lectin MLI Extract containing 40 µg/mL oleanolic acid Extract containing 15 ng/mL lectin MLI and 30 µg/mL oleanolic acid | Human acute myeloid leukemia cell line HL-60 | Downregulation of BIRC5, XIAP, p53 and claspin | Delebinski et al. ( | |
Extract containing 1–40 ng/mL lectin MLI Extract containing 10–60 µg/mL oleanolic acid Extract containing 1–40 ng/mL lectin MLI and 10–60 µg/mL oleanolic acid | Human Ewing sarcoma cell lines TC-71 and MHH-ES-1 | Downregulation of BIRC5, XIAP, MCL1 and CLSPN, | Twardziok et al. ( | ||
Extract containing 2.5–10 ng/mL lectin MLI Extract containing 40–60 µg/mL oleanolic acid Extract containing 2.5–10 ng/mL lectin MLI and 40–60 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B and Saos-2 | Downregulation of BIRC5, XIAP, BCL2, and CLSPN | Kleinsimon et al. ( | ||
Extract containing 5 ng/mL lectin MLI Extract containing 40 µg/mL oleanolic acid Extract containing 5 ng/mL lectin MLI and 40 µg/mL oleanolic acid | Human alveolar Rhabdomyosarcoma cell lines RH-30 and RMS-13 | Downregulation of BIRC5, XIAP, BCL2, BCL2L1 and MCL1 | Stammer et al. ( | ||
| 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | Downregulation of BCL2 | Mishra et al. ( | ||
| Lectin isolated from | 10 ng/mL | Human hepatocarcinoma cells SK-Hep-1 and Hep3B | Lyu et al. ( | ||
| Abnoba | 20 µg/mL | Human myeloid leukemia cell line K562 | Downregulation of Mcl-1 | Park et al. ( | |
| 1,7-bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Upregulation of Bcl-2 and Bcl-xL | Fan et al. ( | |
| Proapoptotic proteins | 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | Upregulation of Bax | Mishra et al. ( | |
| Lectin isolated from | 10 ng/mL | Human hepatocarcinoma cells SK-Hep-1 and Hep3B | Lyu et al. ( | ||
Extract containing 2.5–10 ng/mL lectin MLI Extract containing 40–60 µg/mL oleanolic acid Extract containing 2.5–10 ng/mL lectin MLI and 40–60 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B and Saos-2 | Kleinsimon et al. ( | |||
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 2.5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Downregulation of Bax | Fan et al. ( | |
| STAT3 | Extract containing 10 ng/mL lectin MLI Extract containing 60 µg/mL oleanolic acid Extract containing 5 ng/mL lectin MLI and 50 µg/mL oleanolic acid | Human osteosarcoma cell lines 143B, Saos-2 and U2OS | Dephosphorylation of STAT3 at Tyr705 and Ser727, down-regulation of total STAT3 and its direct downstream targets BIRC5 and C-MYC | Kleinsimon et al. ( | |
| Abnoba | 5–20 µg/mL | Human hepatocellular carcinoma cell line Hep3B | Reduction of C-MYC protein levels which might be mediated by the ubiquitin–proteasome system | Yang et al. ( | |
| Telomerase | Lectin isolated from | 10 ng/mL | Human cancer cell line A253 | Inhibition of telomerase activity through downregulation of hTERT | Choi et al. ( |
| ROS | 0.015–150 µg/mL | Human leukemia cell lines Jurkat E6.1 and THP1 | ROS mediated DNA fragmentation | Mishra et al. ( | |
| 1,7-Bis(4-hydroxyphenyl)-1,4-heptadien-3-one isolated from | 5–20 µM | Human lung cancer cell lines A549 and NCI-H292 | Promotion of ROS generation | Fan et al. ( |
Pharmacological activity of Viscum species—in vivo studies
| Pharmacological activity | Part | Host tree | Extraction solvent | Compounds | Dose | Route of administration | Study duration | Experimental design | Results | References | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antihypertensive activity | Fresh leaves | Citrus | Aqueous | 150 mg/kg, daily | Orally | 6 weeks | Normotensive, renal artery-occluded hypertensive and salt-induced hypertensive rats | Decrease in arterial blood pressure without alteration in heart rate, antihypertensive effect might involve sympathetic mechanism | Ofem et al. ( | ||
| Fresh steams | Ethanolic, ether and ethyl acetate | 3.33 × 10−5, 1.00 × 10−4, 3.33 × 10−4, 1.00 × 10−3 mg/kg | Intraperitoneally | Atropine sulfate and hexocycline treated rats | Ethanolic extract exhibited activity even on the lowest dose, the ether and ethyl acetate extracts exhibited activity only by higher doses, antihypertensive effect might involve muscarinic receptors | Radenkovic et al. ( | |||||
| Dried leaves | Pear | Aqueous | 250 mg/kg, daily | Orally by gavage | 24 days | Isoproterenol-induced heart failure in rats | Improvement in all parameters of heart failure including left ventricular diameters, ejection fraction, serum NT-proBNP levels and histopathological changes; decrease in levels of NO, iNOS and hs-CRP | Karagöz et al. ( | |||
| 0.6–2.8 g, daily | Orally | 6 weeks | An open study in 120 patients with light to moderate hypertension (WHO grade I-II) | Decrease in systolic pressure (in rest and during physical exercise) | Committee on Herbal Medicinal Products ( | ||||||
| 5 drops of drug every 5 min up to 4 administrations | Sublingually | 264 patients with diagnosis of hypertension | Time of arterial blood pressure reduction was less for the group of patients who received the natural treatment | Montero et al. ( | |||||||
| Ethanolic extract manufactured according to Homoeopathic Pharmacopoeia of India | 10 drops of drug in 30 ml of distilled water, three times a day | Orally | 12 weeks | 37 newly diagnosed hypertensive patients | Decrease in systolic and diastolic pressure, decrease in serum triglyceride | Poruthukaren et al. ( | |||||
| Dried herb | Methanolic | 200 and 400 mg/kg, daily | Orally | 4 weeks | L-NAME-induced hypertensive rats | Antihypertensive effect might be attributed to diuretic, nephroprotective and hypolipidemic actions, and might be due to the presence of triterpenoids | Bachhav et al. ( | ||||
| Cuticular wax | Oleanolic acid | 60 mg/kg, daily | Intraperitoneally | 15 days | Glucocorticoid (dexamethasone)-induced hypertensive rats | Decrease of the systolic blood pressure, which might be connected with its antioxidant and NO releasing action | Bachhav et al. ( | ||||
| Cuticular wax | Oleanolic acid | 60 mg/kg, daily | 4 weeks | L-NAME-induced hypertensive rats | Oleanolic acid did not affected NO level and its antihypertensive effect might be due to diuresis and nephroprotection | Bachhav et al. ( | |||||
| Hematological parameters | Fresh leaves | Citrus | Aqueous | 150 mg/kg, daily | Orally | 6 weeks | High salt-fed rats | Decrease in the red blood cells, packed cell volume, haemoglobin, total plasma protein levels and increase in erythrocyte sedimentation rate | Ofem et al. ( | ||
| Dried leaves | Coffee ( | Aqueous | 400, 800, 1600 and 3200 mg/kg, daily | Orally | 14 days | Healthy rats | Mistletoe parasitizing on kola significantly, in dose dependent manner, decreased platelets count, mistletoe parasitizing cocoa and coffee reduced haemoglobin concentration, all the extracts reduced packed cell volume, red blood cell and increased white blood cells | Ladokun et al. ( | |||
| Antiglycemic, antilipidemic and insulinotropic effect | Dried leaves | Ethanolic | 250, 500, 750, 1000 mg/kg | 10 h | Normalglycemic and streptozotocin-induced diabetic rats | Reduction in fasting blood glucose level | Nwaegerue et al. ( | ||||
| Dried herb | Apricot ( | Aqueous and ethanolic | 500 mg/kg | Orally by gastric gavage | 8 days | Streptozotocin-induced diabetic rats | Antidiabetic effect of mistletoe depends on the host tree | Orhan et al. ( | |||
| Fresh leaves | Aqueous | 100 mg/kg | Intravenously | 3 h | Normalglycemic and streptozotocin-induced diabetic rats | No effect on glucose level in normal rats but decrease of the blood glucose level in the diabetic rats, increase of the insulin secretion in normal rats and in the diabetic group | Eno et al. ( | ||||
| Dried herb | Methanolic | 100 mg/kg, daily | 3 weeks | Streptozotocin-induced diabetic rats | Reduction in fasting blood glucose level, HbA1c, serum triglyceride, urea, lactate dehydrogenase, α-amylase and low density lipoprotein cholesterol, increase of high density lipoprotein cholesterol | Adaramoye et al. ( | |||||
| Dried leaves | Ethanolic | 100 mg/kg, daily | Orally by gavage | 10 days | Streptozotocin-induced diabetic rats | No significant difference in glucose level, reduction in oxidative stress | Turkkan et al. ( | ||||
| Dried leaves | Citrus | Aqueous | 150 mg/kg, daily | Orally with syringe and orogastric tube | 3 weeks | Streptozotocin-induced diabetic rats | Reduction in fasting blood glucose level | Nna et al. ( | |||
| Dried leaves | Oil been ( | Aqueous | 200 mg/kg | Intraperitoneally | 4 h | Fasted normalglycemic rats | Decrease in blood glucose level | Ohiri et al. ( | |||
| 400 mg/kg | Alloxan-induced diabetic rabbits | ||||||||||
| Dried leaves | Oak | Aqueous | 500 and 1000 mg/kg, daily | Orally by gavage | 3 days | Alloxan-induced diabetic rats | Decrease in serum glucose concentration and increase in the serum insulin level | Shahaboddin et al. ( | |||
| Dried leaves | Sweet orange ( | Aqueous | 100 mg/kg, daily | Orally by gavage | 14 days | Alloxan-induced diabetic rats | The strongest activity was exhibited by extracts of mistletoe growing on | Umoh et al. ( | |||
| Dried leaves | Ethanolic | 2 mg/kg, 16 h | Intraperitoneally | 54 h | Alloxan-induced diabetic rats | Decrease in fasting blood glucose level | Ibegbulem and Chikezie | ||||
| Dried herb | Oak ( | Protein fraction | 50—400 µg/ml | Intraperitoneally | 10 days | Alloxan-induced diabetic mice | Decrease in the blood glucose level and volume of drinking water | Kim et al. ( | |||
| Dried herb | Oak | Aqueous and ethanolic | Betulin and oleanolic acid | Diet containing 0.2 or 0.6% of extract | Orally | 8 weeks | Partial pancreatectomized rats | Ethanolic extract made β-cell mass greater by increasing β-cell proliferation and decreasing its apoptosis | Ko et al. ( | ||
| Dried herb | Methanolic | 500 mg/kg, daily | Orally by gavage | 4 weeks | Streptozotocin-induced diabetic rats | Reduction in the fasting blood glucose level; increase of the level of insulin, reduction of total cholesterol, trigliceryde and low density lipoprotein cholesterol and increase of high density lipoprotein cholesterol | Abdel-Sattar et al. ( | ||||
| Hepatoprotective activity | Leaves | Ethanolic | 1 g/kg | Orally | Paracetamol-induced hepatotoxity in rats | Reduction of ALT, ALP levels, no influence on the levels of total bilirubin and total protein | Ogbonnanya et al. ( | ||||
| Dried leaves | Cocoa ( | Methanolic | 1000–5000 mg/kg, daily | Orogastrically | 7 days | Paracetamol-induced hepatotoxity in rats | No significant difference in AST, ALT and ALP for | Yusuf et al. ( | |||
| Dried leaves | Citrus | Aqueous | 150 mg/kg, daily | Orally (syringe and or gastric tube) | 6 weeks | High salt diet rats | Decrease in serum total bilirubin, serum conjugated bilirubin and serum unconjugated bilirubin | Ofem et al. ( | |||
| Dried leaves | Citrus | Aqueous | 150 mg/kg, daily | Orally (syringe and or ogastric tube) | 3 weeks | Streptozotocin-induced diabetic rats | Decrease in serum total bilirubin, serum conjugated bilirubin and serum unconjugated bilirubin | Nna et al. ( | |||
| Viscum Fraxini-2 ( | Ash | Aqueous | 0.1 and 0.2 ml/kg, once weekly | Subcutaneously | 30 days | Carbon tetrachloride-induced hepatotoxity in rats | Decrease in ALT, AST and ALP levels, restoration of the normal architecture of the liver tissue with minimal fibrosis | Abdel-Salam et al. ( | |||
| 0.2 ml/kg of mistletoe + 25 mg/kg of sylimarin, once weekly | |||||||||||
| Iscador Qu ( | Fresh herb | Oak ( | Fermented, aqueous extract | 380 ng/ml of lectins, 14 mg/ml of viscotoxines | Two 5 mg ampules, three times weekly | Subcutaneously | 12 months | 5 patients with chronic hepatitis C | 6–20 fold reduction in viral load (HCV-RNA) and complete remission of elevated AST and ALT in two out of five patients, an increase of HCV RNA in one patient | Tusenius et al. ( | |
| Iscador Qu ( | Fresh herb | Oak ( | Aqueous | 750 ng of lectins | 10 mg, three times weekly | Subcutaneously | 12 months | 21 patients with chronic hepatitis C | Decrease in ALT and AST during the 12 months treatment and slight increase after treatment end | Tusenius et al. ( | |
| Abnoba | Fresh herb | Oak | Aqueous | 1000 ng of lectins | 0.15 mg, three times weekly | ||||||
| Abnoba | Fresh herb | Oak | Aqueous | 65–3610 ng of lectins (mean weekly dose) | Three times a week | Subcutaneously | 9 months | 25 patients with chronic hepatitis C and elevated alanine aminotransferase (ALT) levels | None of the patients had complete or partial normalization of ALT or HCV-RNA levels during treatment period, mean ALT did not change during the study | Huber et al. ( | |
| Dried steams and leaves | Aqueous | Alkaloid fraction | 120 mg/kg, daily | Orally by gastric gavage | 8 weeks | Carbon tetrachloride-induced hepatic fibrosis in rats | Decrease of hepatic fibrosis; reduction in mRNA levels of TGF-β1, procollagen I and TIMPs; increase in TGF-β1, TGF-β1 receptor, phosphorylated Smad 2 and α-SMA proteins in liver tissues; increase in Smad 7 level | Jiang et al. ( | |||
| Antiepileptic activity | Fresh leaves | Citrus | Aqueous | 50 and 150 mg/kg | Orally | Maximum electro shock, isoniazid- and pentylenetetrazole-induced seizures in mice and rats | Reduction in various phases of epileptic seizures, increased latency to the first convulsion, increased convulsion onset and reduction in seizure duration | Gupta et al. ( | |||
| Dried herb | Maple ( | Aqueous and aqueous-ethanolic | 100 mg/kg | Intragastrically | 2 days | Pentylenetetrazole-induced seizures in mice | Effective against pentylenetetrazole-induced seizures | Tsyvunin et al. ( | |||
| Willow ( | Ethanolic | ||||||||||
| Viscum Mali e planta tota | Apple tree | Initially given in strength D5, 10 granules BID, equivalent to a 1:100,000 dilution of the whole plant extract, later increased to D2, equivalent to a 1:100 dilution, 10 granules twice a day | 12 weeks | 4½-year-old girl suffering from childhood absence epilepsy | The dose increase of Viscum Mali, in addition to an existing combination with valproic acid and clobazam, may have played a key role in achieving seizure freedom for this child | von Schoen-Angerer et al. ( | |||||
| Dried stems | Methanolic | 50 and 100 mg/kg | Intraperitoneally | Pentylenetetrazole-, bicuculline- and N-methyl-DL-aspartic acid- induced seizures in mice | Delayed the onset of pentylenetetrazole—and bicuculline-induced seizures and reduction in the number of convulsing animals; moderate effect against N-methyl-DL-aspartic acid-induced tonic seizures | Amabeoku et al. ( | |||||
| Dried herb | Methanolic | 100 and 200 mg/kg, daily | Orally | 7 days | Maximum electro shock- and pentylenetetrazole- induced seizures in rats | Reduction in duration of hind limb extensor phase and increase in the latency to convulsions | Geetha et al. ( | ||||
| Fresh herb | Chloroform and methanolic | Syringaresinol | 150 and 300 mg/kg for extracts, 10 and 20 mg/kg for isolated compound | Orally | 7 days | Picrotoxin- induced seizures in rats | Extracts and syringaresinol delayed the onset of tonic convulsions, increase in the brain GABA levels in rats treated with the methanolic extract | Geetha et al. ( | |||
| N-methyl- | Only the methanolic extract and syringaresinol antagonized the N-methyl- | ||||||||||
| Sedative activity | Fresh leaves | Citrus | Aqueous | 50 and 150 mg/kg | Orally | Mice placed in actophotometer | Reduction in locomotor activity | Gupta et al. ( | |||
| Fresh leaves | Citrus | Aqueous | 50 and 150 mg/kg | Orally | Pentobarbital- induced sleeping time in mice | Increase in duration of sleeping time | Gupta et al. ( | ||||
| Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 200 and 400 mg/kg for extract, 25 and 50 mg/kg for fractions | Orally | Open field test on mice | Reduction in rearing and crossings | Kumar et al. ( | |||||
| Dried leaves | Methanolic | 300 and 500 mg/kg | Orally | Open field test and hole cross test in mice | Reduction in spontaneous motor activities | Khatun et al. ( | |||||
| Hypnotic activity | Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 200 and 400 mg/kg for extract, 25 and 50 mg/kg for fractions | Orally | Thiopentone sodium induced-sleeping time assay in mice | Increase in the duration of sleep in mice | Kumar et al. ( | ||||
| Antipsychotic activity | Fresh leaves | Citrus | Aqueous | 50 and 150 mg/kg | Orally | Apomorphine-induced stereotypy in mice and rats | Significantly reduction in the stereotyped behaviour | Gupta et al. ( | |||
| Fresh leaves | Citrus | Aqueous | 50 and 150 mg/kg | Orally | Haloperidol-induced catalepsy in mice and rats (bar test) | Enhancement in cataleptic effect of haloperidol | Gupta et al. ( | ||||
| Antianxiety activity | Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 50 and 100 mg/kg for extract, 5 and 10 mg/kg for fractions | Orally | Elevated plus-maze test on mice (EPM model) | The number of entries and time spent in open arms in the elevated plus-maze test were significantly increased | Kumar et al. ( | ||||
| Antistress activity | Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 200 and 400 mg/kg for extract, 25 and 50 mg/kg for fractions | Orally | Cold swim test on mice | Reduction in time spent by mice in the immobile state | Kumar et al. ( | ||||
| Antidepressant activity | Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 200 and 400 mg/kg for extract, 25 and 50 mg/kg for fractions | Orally | Despair swim test on mice | Reduction in the duration of immobility in mice | Kumar et al. ( | ||||
| Analgesic activity | Dried herb | Methanolic and its ethyl acetate and 1-butanol fractions | 200 and 400 mg/kg for extract, 25 and 50 mg/kg for fractions | Orally | Tail immersion test was conducted by recording tail withdrawal from heat (flicking response) in mice | Significant analgesic activity | Kumar et al. ( | ||||
| Dried leaves and stems | Apricot ( | Ethyl acetate | 2′-Hydroxy-4′,6′-dimethoxy-chalcone-4- | 125 and 250 mg/kg for extract and 30 mg/kg for isolated compounds | Orally | p-Benzoquinone-induced writhing test in mice and carrageenan-induced hind paw edema model in mice | Ethyl acetate fraction and isolated compounds exhibited antinociceptive and anti-inflammatory activity | Orhan et al. ( | |||
| Dried leaves | Methanolic | 300 and 500 mg/kg | Orally | Acetic acid-induced writhing model in mice and formalin-induced paw licking in mice | Writhing and paw licking inhibition | Khatun et al. ( | |||||
| Alzheimer’s disease | Dried leaves | Orange tree | Aqueous | 100 mg/kg, daily | Orally | 21 days | Aluminum chloride-induced Alzheimer’s disease in mice | Increase in the brain-derived neurotrophic factor (BDNF); reduction of aluminum chloride-induced memory impairment and oxidative damage | Ademola et al. ( | ||
| Dried herb | Methanolic | 25 and 50 mg/kg, daily | Orally | 7 days | Intracerebroventricular injection of amyloid β protein in mice | Protection from memory impairment induced by intracerebroventricular injection of amyloid β protein | Jang et al. ( | ||||
| Mood | Eurixor | Fresh herb | Aqueous | Lectin (ML-1) | 1 ng/kg body weight, twice a week | Subcutaneously | 12 weeks | Breast cancer patients (n = 36) | Increased levels of plasma beta-endorphin | Heiny and Beuth | |
| Eurixor | Fresh herb | Aqueous | Lectin (ML-1) | 0.5–1.0 ng /kg body weight, twice a week | Subcutaneously | 24 weeks | Breast cancer patients (n = 47) | Increased levels of plasma beta-endorphin | Heiny et al. ( | ||
| Antiobesity activity | Dried herb | Oak | Aqueous | 3 g/kg, daily | Orally | 15 weeks | High-fat diet-induced obesity in mice | Reduction in body and epididymal fat pad weights | Jung et al. ( | ||
| Dried herb | Oak | Aqueous and ethanolic | Betulin and oleanolic acid | Diet containing 0.2 or 0.6% of extract | Orally | 8 weeks | Partial pancreatectomized rats | Reduction in epididymal fat mass by increasing fat oxidation | Ko et al. ( | ||
| Endurance capacity | Dried herb | Oak | Aqueous | 3 g/kg, daily | Orally | 15 weeks | Endurance test with treadmill in high-fat diet- induced obesity mice | Mistletoe treated mice run twice as far as high-fat diet mice | Jung et al. ( | ||
| Dried herb | Oak | Aqueous | 400 and 1000 mg/kg, daily | 1 week | Endurance test with treadmill in mice | Mistletoe treated mice run 2.5-times longer than control mice, plasma lactate levels of exhausted mice were significantly lower | Jung et al. ( | ||||
| 25—400 mg/kg, daily | Forced swim test in mice | The swimming time to exhaustion was prolonged by as much as 212% | |||||||||
| Leaves | Oak | Aqueous | 500 mg/kg, daily | Orally | 2 weeks | Endurance test with treadmill in mice | Decreases in level of plasma lactate dehydrogenase, increase in the plasma FFA level | Lee et al. ( | |||
| Whole plant | Aqueous | diet Containing 0.3 and 1.5% of extract | Orally | 4 weeks | Treadmill and swimming pool tests in mice | Increased swimming activity and elevated running times on the treadmill | Jeong et al. ( | ||||
| Activity against muscle decline | Whole plant | Aqueous | 200 and 500 mg/kg, twice a day | Orally by gavage | 15 days | Denervated mice | Decrease in denervation, decrease in the expression of Atrogin-1, no effect on Murf1 expression | Jeong et al. ( | |||
| Diet containing 0.3 and 1.5% of extract | 4 weeks | Mice | Increased whole body weights, a higher weight of quadricepses, increased grip strengths, increased swimming activity and elevated running times on the treadmill, increased skeletal muscle area and diameter | ||||||||
| Whole plant | Aqueous | 1 and 2 g/d | Orally | 12 weeks | Randomized controlled trial with 67 patients aged 55–75 | Significant differences were found in atrogin-1 mRNA, myogenin mRNA and insulin growth factor 1 receptor phosphorylation | Lim et al. ( | ||||
| Nephroprotective activity | Helixor M ( | Fresh herb | Apple tree ( | Aqueous | 5 mg/kg | Intraperitoneally | 10 days | Methotrexate-induced acute oxidative stress and nephrotoxicity in rats | Improvement in the glutathione peroxidase and superoxide dismutase activities, decrease in the NO and myeloperoxidase levels was not significant | Sakalli Çetin et al. ( | |
| Oleanolic acid | 40, 60 and 80 mg/kg, daily | Orally | 8 days | Gentamicin-induced nephrotoxicity | Decrease in serum and urine levels of creatinine, albumin and urea | Patil et al. ( | |||||
| Diuretic activity | Dried herb | Methanolic | 100, 200 and 400 mg/kg | Orally | 24 h | Rats | Dose-dependent increase in urine excretion volume, significant saluretic and natriuretic activity, the Cl(-)/Na( +) + K( +) ratio, which indicates carbonic anhydrase mediated activity remained unaffected | Jadhav et al. ( | |||
| Dried herb | Methanolic | 100, 200 and 400 mg/kg | Orally | 24 h | Rats | Dose-dependent increase in urine excretion volume, significant saluretic and natriuretic activity | (Jadhav et al. ( | ||||
| Wound healing | Liphohilic extract | Ointment | Topical treatment | 12 patients with 15 BCC lesions | Achievement of hemostasis in bleeding tumor wounds and after a prolonged treatment period a wound epithelialization with a thin epithelial layer | Kunz et al. ( | |||||
| Whole plant | Ethanol | 1% extract ointment | Incision, excision and dead space wound model in rats | Reduction in wound area, faster re-epithelization rate | Garg et al. ( | ||||||
| Antiulcer activity | Dried herb | Methanolic | 200 and 400 mg/kg | orally | Ethanol-induced ulcer model and pylorus ligation ulcer model in rats | Inhibition of the gastric lesions | Naganjaneyulu et al. ( | ||||
| Antibacterial activity | Dried leaves | Cocoa | Methanolic | 1000 mg/kg, daily | 7 days | Rats with infections of | Heamatological and histopathological analyses showed therapeutic effects of the extract | Yusuf et al. ( |
Fig. 2Mechanism of cardiac activity of mistletoe. Mistletoe compounds acting on receptor of endothelial cell might activate influx of Ca2+ ions leading to activation of NOS. NOS catalyzes formation of NO from L-arginine. NO diffuses to smooth muscle cell. Once sGC is activated by NO, GTP to cGMP conversion is triggered. cGMP activates PKG leading to reducing intracellular Ca2+ (by inhibition of Ca2+ influx through ligand gated Ca2+ channels and release from cellular stores). Proposed mechanism is confirmed by the fact that mistletoe induces NOS-2 and NOS-3 overexpression which is connected with increase in NO and cGMP production
Fig. 3Mechanism of antidiabetic activity of mistletoe. Mistletoe increases the secretion of insulin and insulin precursor, C-peptide. Insulin binds to tyrosine kinase receptor (RTK). The activated receptor phosphorylates the IRS-1 protein leading to activation of PI3K which catalyzes the addition of phosphate group to PIP2, converting it to PIP3. PIP3 activates PDK1 leading to AKT phosphorylation, recruitment of the glucose transporter GLUT-4 to the membrane and glucose inflow. Mistletoe enhances the expression of GLUT-4, IRS-1 and AKT. Furthermore, protein fraction of mistletoe upregulates transcription factors PDX-1 and beta2 (neuroD). PDX-1 and beta2 become phosphorylated (this process might be mediated by PI3K and ERK1/2 pathways) and regulate insulin gene transcription
Fig. 4Mechanism of hepatoprotective activity of mistletoe, TGFβ/Smad pathway. TGFβ1 binds to its receptor, which consists of two type I and two type II subunits. Type II subunit phosphorylates type I subunit, which then phosphorylates Smad 2 and Smad 3. Phosphorylated Smad 2 and Smad 3 bind with Smad 4 and together they move into the nucleus to regulate expression of target genes. Smad 7 is an inhibitory Smad that negatively regulates Smad 2/3 activation. In vivo study showed that mistletoe alkaloid fractions downregulate TGF-β1, TGF-β1 receptor, phosphorylated Smad 2 and α-SMA proteins as well as downregulate the mRNA levels of TGF-β1, collagen I and TIMP-1. In contrast, Smad 7 level is upregulated. In vitro study showed that mistletoe alkaloid fractions induce Smad 7 expression and inhibit the expression of α-SMA, TGFβ1, TGF-β1 receptor, Smad 2 and TIMP-1
Fig. 5Mechanism of neuropharmacological activity of mistletoe, GABAergic signalling. Mistletoe compounds might be positive allosteric modulators of GABAA receptor. They might bind to benzodiazepine site increasing the binding affinity of the receptor for GABA. This results in increased frequency of chloride ion channel opening, increased influx of chloride ions and hyperpolarization leading to anticonvulsant, sedative and anxiolytic activity
Fig. 6Mechanism of neuropharmacological activity of mistletoe, BDNF signalling. Mistletoe has been reported to increase brain-derived neurotrophic factor (BDNF) level. BDNF binds to tyrosine receptor kinase B leading to its phosphorylation and activation of signaling pathways. The P13K pathway activates AKT leading to neuronal survival whereas MAPK/ERK pathway leads to neuronal growth and differentiation
Fig. 7Probable mechanism of antiobesity activity of mistletoe. LPL converts triacylglycerides into free fatty acids. Free fatty acids are moved into the cell and activated to acyl-CoA. CPT1 converts acyl-CoA to acylcarnitine, which is transported into the mitochondria by CAT. CPT2 converts acylcarnitine back to acyl-CoA, and then acyl-CoA enters β-oxidation pathway. Acetyl-CoA goes into TCA cycle. Citrate exits mitochondria and is converted to acetyl-CoA, which is carboxylated to malonyl-CoA by ACC. FAS undergoes the reductive synthesis of palmitate which is converted to palmitiyl-CoA leading to formation of triacylogliceryes. Additionally, malonyl-CoA inhibits CPT-1. Mistletoe decreases expression of FAS, ACC, ACS and LPL and decreases SREBP-1c, C/EBP-α, and PPAR-γ mRNA expression
Fig. 8Probable effect of mistletoe on muscle mitochondrial activity. Two major genes related to mitochondrial biogenesis and function are SIRT-1 and PGC-1α. PGC-1α translocates into the nucleus where it is phosphorylated by AMPK and deacetylated by SIRT-1. Once phosphorylated and deacetylated, PGC-1α activity is increased, leading to increased transcription of mitochondrial genes. Korean mistletoe increases the mRNA expression of PGC-1α and SIRT-1 and increases the expression of PGC-1α transcriptional targets such as PGC-1β, NRF-1, ERRα, Tfam, PPARβ/δ, myoglobin and TNNI2
Fig. 9Probable effect of mistletoe against muscle decline. IGF1 binds to IGF1 receptor leading to activation of PI3K/AKT/mTOR pathway. Mistletoe leads to higher phosphotylation of AKT resulting in activation of P70S6K, upregulation of myoD and myogenin expression and myogenesis. Mistletoe decreases phosphorylation of PTEN which dephosphorylates PIP3, increasing PIP2 level and resulting in a decreased AKT activity. Furthermore, mistletoe decreases expression of REDD2 which inhibits mTOR pathway. Mistletoe increases phosphorylation of FoxO supporting the observation that mistletoe could induce the phosphorylation of AMPK, which is a repressor of FoxO. AKT also causes phosphorylation and nuclear exclusion of FoxO which is key molecule inducing muscle atrophy by stimulating Murf1 and Atrogin-1. Additionally, FoxO-dependent activation of muscle atrophy is inhibited by PGC-1α